Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2025.1641399OncologyCorrectionCorrection: TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMsLeFuyin1†YangLilan2†HanYiwen3ZhongYanying1ZhanFuliang1FengYing1HuHui1*ChenTingtao13*TanBuzhen1*1Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, China2Department of Obstetrics & Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, China3Institute of Translational Medicine, Nanchang University, Nanchang, China
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMs By Le F, Yang L, Han Y, Zhong Y, Zhan F, Feng Y, Hu H, Chen T and Tan B (2021) Front. Oncol. 11:704001. doi: 10.3389/fonc.2021.704001A2780/DDP cellscisplatin (DDP) resistancetriptolide (TPL)PI3K/AKT/NF-κB- pathwaytumor-associated macrophages (TAMs)section-in-acceptanceCancer Immunity and Immunotherapy
There was a mistake in Figure 3 as published. In Figure 3C, there are instances of duplicated areas between some images due to carelessness. Specifically, these occur between: Migration-C and Invasion-Co-C; Invasion-C and Migration-12.5nM TPL; Invasion-C and Invasion-6.25nM TPL; Invasion-Co-C and Invasion-12.5nM TPL; Invasion-6.25nM TPL and Migration-25nM TPL; Invasion-6.25nM TPL and Migration-12.5nM TPL. The corrected Figure 3 appears below.
Tumor-associated macrophage (TAM) cell supernatant slightly improves the proliferation, migration, and invasiveness of A2780/DDP cells, but triptolide (TPL) reverses these effects. (A) TPL was diluted to varying concentrations with TAM cell supernatant, and then added to A2780/DDP cells; cell proliferative ability was measured 24 h later. (B) Quantitative analyses of the proliferative capacity of A2780/DDP cells are shown in (A). (C) Representative transwell migration and invasion assay of A2780/DDP cells after treatment with TPL. (D, E) Quantification of migratory and invasive capacities of A2780/DDP in (C). *P < 0.05, **P < 0.01, and ***P < 0.001. (F, G) Representative extracellular matrix-adhesion experiment using A2780/DDP cells treated with different concentrations of TPL for 3 or 6 h. *P < 0.05. ns, no significance.
Panel A shows EdU, DAPI, and overlay images illustrating cell proliferation under different conditions. Panel B is a bar graph of cell proliferation rates, with variations across treatments. Panels C depict migration and invasion assays, showing cell behavior under various conditions. Panels D and E provide bar graphs comparing migration and invasion fold changes. Panels F and G display A2780/DDP cell counts at three and six hours, respectively, showing differences under specific treatments.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.